



(11) **EP 1 177 289 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
23.04.2008 Bulletin 2008/17

(51) Int Cl.:
C12N 15/12 (2006.01) C07K 14/705 (2006.01)
A61K 38/17 (2006.01) G01N 33/68 (2006.01)

(21) Application number: **00927035.6**

(86) International application number:
PCT/EP2000/003683

(22) Date of filing: **25.04.2000**

(87) International publication number:
WO 2000/068377 (16.11.2000 Gazette 2000/46)

(54) **RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE**

REKOMBINANTES PLÄTTCHENKOLLAGENREZEPTORGLYKOPROTEIN UND DESSEN PHARMAZEUTISCHE VERWENDUNG

GLYCOPROTEINE VI DE RECONSTRUCTION DU RECEPTEUR DE COLLAGENE DES PLAQUETTES ET UTILISATION PHARMACEUTIQUE DE CETTE DERNIERE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
LT LV RO SI

(30) Priority: **07.05.1999 EP 99109094**

(43) Date of publication of application:
06.02.2002 Bulletin 2002/06

(60) Divisional application:
08004264.1

(73) Proprietor: **Sanofi-Aventis Deutschland GmbH**
65929 Frankfurt am Main (DE)

(72) Inventor: **CLEMETSON, Kenneth, J.**
CH-3065 Bern (CH)

(56) References cited:
WO-A-95/11259

- **GIBBINS JONATHAN M ET AL: "Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain." FEBS LETTERS, vol. 413, no. 2, 1997, pages 255-259, XP002143941 ISSN: 0014-5793**

- **JANDROT-PERRUS MARTINE ET AL: "Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha-2-beta-1." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 43, 1997, pages 27035-27041, XP002143942 ISSN: 0021-9258**
- **GIBBINS JONATHAN M ET AL: "The p85 subunit of phosphatidylinositol 3-kinase associated with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 51, 18 December 1998 (1998-12-18), pages 34437-34443, XP002143943 ISSN: 0021-9258**
- **CLEMETSON JEANNINE M ET AL: "The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 41, 8 October 1999 (1999-10-08), pages 29019-29024, XP002143944 ISSN: 0021-9258**
- **MIURA Y: "Platelet glycoprotein VI" EMBL DATABASE ; ACCESSION NUMBER AB035073, 14 January 2000 (2000-01-14), XP002143945**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 177 289 B1

Description

[0001] The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit interaction of platelets and collagen. GPVI on the platelet surface is modified during the platelet lifetime in vivo and can therefore be used as a marker of the platelet age profile.

[0002] Glycoprotein VI is a 62/65 kDa (non-reduced/reduced respectively) platelet membrane glycoprotein which forms a complex together with the Fc γ common subunit. The GPVI subunit contains the collagen binding site and the Fc γ subunit is responsible for signalling. The complex forms one of the major collagen receptors on the platelet surface, critical for platelet activation in response to collagen. The recognition sequence on collagen consists of (GlyProHyp)_n sequences. Patients are known from Japan who have a genetic deficiency of GPVI. They have mild bleeding problems and their platelets respond only weakly to collagen, presumably via other receptors. A great deal has been learned about the signalling cascades originating at GPVI which strongly resemble those from immune receptors including T-cell receptors, B-cell receptors and natural killer cell receptors. These cascades involve src family tyrosine kinases such as Fyn and Lyn as well as p72^{SYK} and many other tyrosine kinases and phosphatases and adaptor proteins such as LAT. A main target of these cascades is activation of phospholipase C γ 2 which splits phospholipids to give the second messengers diacylglycerol and IP₃. GPVI is thought to be involved in activation of the platelet integrin α 2 β 1 which has a major role in platelet adhesion to damaged vessel wall. Mice with the Fc γ subunit "knocked-out" have platelets which still show responses to collagen implying that the resting state of α 2 β 1 may also be regulated by the GPVI/Fc γ complex.

[0003] The platelet collagen receptor GPVI is closely related to the natural killer activatory receptors of the p58KAR family as well as to Fc α R.

[0004] The adhesion and activation of resting, circulating platelets at a site of vascular injury is the first step in a process leading to the formation of a thrombus which is converted into a haemostatic plug. Collagen is one of the major components of the vessel wall responsible for platelet activation. Many types of collagen exist and seven of these are found in the subendothelial layers. Several different receptors for collagen have been identified on platelets but the major ones are now considered to be the integrin α 2 β 1 and the non-integrin GPVI. Although α 2 β 1 is well characterised and both subunits were cloned and sequenced several years ago, the structure of GPVI has remained elusive although several features have been identified. It was determined about twenty years ago that GPVI is a major platelet glycoprotein with a molecular mass in the 60-65 kDa range and an acid pl. Its role as a putative collagen receptor was established following the identification of a patient in Japan with a mild bleeding disorder whose platelets showed a specific defect of response to collagen and lacked this receptor. This patient had also developed autoantibodies to the deficient receptor and these were used to characterise the molecule further. More recently it was established that GPVI is associated non-covalently with the common Fc γ subunit which acts as the signalling part of the complex. It was also demonstrated that the recognition sequence on collagen for GPVI is a repeated Gly-Pro-Hyp triplet within the collagen triple helical structure and that synthetic peptides based on this structure could be used as specific GPVI directed agonists. The GPVI/ Fc γ complex was shown to signal to the platelet interior by an immune receptor-like mechanism, involving activation of p72^{SYK} and leading by a cascade of kinase/phosphatase/adaptor protein interactions to activation of PLC γ 2 and hence to release of granules and platelet aggregation. A further step in characterisation of this molecule was the demonstration that the snake C-type lectin, convulxin, from the Tropical Rattlesnake, *Crotalus durissus terrificus* was able to activate platelets by clustering GPVI through a multimeric interaction. Convulxin was shown to bind specifically to GPVI providing a method for purification of this receptor in conjunction with established approaches.

[0005] Gibbins Jonathan M et al. (FEBS LETTERS, Vol. 413, No. 2, 1997, pp.255-259) analyzed the adhesion and activation of human platelets induced by convulxin and found out that glycoprotein VI and integrin α 2 β 1 are involved.

[0006] Thus, it is clear from the prior art that GPVI seems to be a very interesting compound in many therapeutical fields above all concerning with applications which are related, directly or indirectly, to blood coagulation events which depend on collagen - platelet interaction. It was, therefore, the goal of the present invention is to provide GPVI in a recombinant form and to show its efficiency as direct therapeutical target or as tool for screening of short compounds, especially chemically synthesized or synthesizable compounds having the capability to inhibit or block the natural platelet-collagen interaction.

[0007] The invention relates also to portions or fragments of the GPVI protein which have maintained their biological activity which is the binding to collagen.

[0008] The invention was successful in purifying adequate amounts of GPVI for preliminary characterisation and for peptide sequencing. The sequences were used to design primers for PCR to identify a positive sequence in a DNA library. This DNA sequence was then used as a probe to isolate an almost complete cDNA sequence from the library and missing 5'-sequence was obtained using a RACE method from a platelet cDNA library.

[0009] The invention was also successful in showing the use of recombinant GPVI as therapeutically applicable compound which is capable, when administered in a patient with e.g. damaged blood vessels, to bind to collagen, thus preventing platelets bearing membrane-bound GPVI from binding to said collagen. The recombinant soluble extracellular domain of GPVI contains the collagen binding site and can prevent platelet activation by collagen. It could therefore be applicable to treatment of disease conditions involving increased platelet activation with collagen, such as atherosclerotic plaque rupture, in diseases such as unstable angina or, during surgical treatment such as Percutaneous Transluminal Coronary Angioplasty (PTCA), where arteries are reopened by inflation of a balloon catheter causing considerable damage to the vessel wall and much platelet activation and often resulting in reclosure of the vessel later. The advantage of recombinant GPVI fragments compared to present treatment methods is that they act at an earlier stage by preventing or reducing platelet activation rather than by suppressing events after platelet activation, such as aggregation by GPIIb-IIIa antagonists. Thus, smaller amounts of platelet granule contents are released including growth factors and chemokines which are involved not only in wound repair but in the remodelling of the vessel wall by smooth muscle migration and in attraction of phagocytic cells such as monocytes known to contribute to atherosclerosis. Fab fragment of humanised mouse monoclonal antibodies against GPVI could be used with similar effect to block GPVI on the platelet surface with similar applications as above.

[0010] Recombinant GPVI according to this invention can also be used in a binding assay to collagen to screen for small molecules (in combinatory libraries for example) capable of inhibiting this interaction and which can be used to develop therapeutic compounds which are inhibitors of the collagen-platelet interaction. By suitable derivatisation these compounds are made orally available. Again the main objective is to prepare compounds reducing GPVI-collagen interactions and hence platelet activation in situations where platelets come into contact with collagen. The screening technology as such used in this invention is well established in the prior art. By such screening assays the invention enables finding and developing new targets which can inhibit the natural membrane-bound GPVI on the platelet surface as a collagen antagonist. Such targets which may be small chemical molecules may then be the basis for further inventions.

[0011] Another major application of GPVI and reagents that recognize specific domains of GPVI is as markers of platelet age and functionality. Young platelets are generally thought to be more active and functional than older ones. Young platelets bind to and are activated by the snake venom C-type lectin convulxin, which is specific for GPVI, and as they age both the binding and degree of activation decrease. This can be due to either proteolytic or conformational changes in GPVI or its association with Fc γ due to platelet activation or damage in the circulation. This can be a useful parameter to measure the age and function profile of platelets in patients as well as in normal persons during medical controls. The platelet age profile changes in many diseases affecting the bone marrow or the immune system and could be an important diagnostic criterion if better methods for its determination were available. For example, patients with diseases involving increased platelet turnover will show more young platelets whereas patients on chemotherapy or radiation treatment will show a steadily aging population. Thus, such an age profile can be used for a precise monitoring of treatment. In a normal healthy population very little is known about the age profile distribution and its role as a predictor of changes in health. It is not known whether the changes in GPVI are due to the partial involvement of platelets in haemostatic events and whether changes might be more pronounced in patients with extensive cardiovascular disease. At present thiazole orange is used to detect young reticulated platelets containing mRNA. This mRNA soon decays, restricting the method to only the youngest platelets. Reagents which could be used in such an assay would include GPVI-specific snake venom proteins such as convulxin, or monoclonal or polyclonal antibodies recognising the N-terminal region of GPVI or monoclonal antibodies recognising new sites or conformations exposed by proteolysis of the N-terminal domain or specific conformations present either in the intact molecule and not in the aged one or vice versa or small chemical entities selected to recognise specifically intact GPVI or its modified form. These reagents would be labelled with a fluorescent marker, or together with a fluorescent labelled second antibody or affinity reagent and used in flow cytometry to measure the platelet binding profile. At a later stage alternative, less labour intensive measuring techniques based on automated measuring of platelet profiles could be adopted. Using cell sorting methods with flow cytometry or magnetic beads it should be possible to isolate young and old platelets to examine the factors involved in removal of old platelets from the circulation. Reagents recognizing specific forms of GPVI would be a key to such studies.

[0012] Therefore, it is an object of the present invention to provide a DNA coding for Glycoprotein VI, especially the sequence of Fig. 2.

[0013] It is a further object of this invention to provide a DNA coding for Glycoprotein VI comprising the amino acid sequences of Fig. 1a and 1b.

[0014] It is another object of this invention to provide a pharmaceutical composition comprising recombinant GPVI together with a pharmaceutically acceptable diluent, carrier or excipient, and its use for the manufacture of a medicament in the therapeutical field of thrombotic and cardiovascular events and disorders related to platelet-collagen interactions

[0015] Another object of the invention is the use of recombinant GPVI in a screening tool for detecting specific inhibitors of platelet-collagen interactions.

[0016] Another object of the invention is the use of GPVI as a marker for platelet age and exposure to cardiovascular

diseases.

[0017] Possible medical indications and applications, respectively, are, for example, unstable angina pectoris, PTCA, use of stents in this field, operations on coronary vessels, general operations on blood vessels, operations which may damage larger blood vessels such as hip joint operations. Moreover, all indications are included which relate to thromboembolic events caused by disorders of the interaction between the vessel wall and the coagulation system with a high risk of formation of thrombi and blocking of vessels.

[0018] As indicated above, the GPVI protein and fragments thereof according to the present invention are suitable as pharmaceutically effective compounds in pharmaceutical compositions and combinations.

[0019] The pharmaceutical formulations according to the invention optionally may comprise additional active ingredients like anti-coagulants such as hirudin or heparin or thrombolytic agents such as plasminogen activator or hementin or antagonists to other platelet receptors such as GPIIb-IIIa antagonists like abciximab or eptifibatide or ADP-receptor antagonists such as clopidogrel.

[0020] The novel protein, and its biological active fragments respectively, according to the invention may form pharmaceutically acceptable salts with any non-toxic, organic or inorganic acid. Inorganic acids are, for example, hydrochloric, hydrobromic, sulphuric or phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Examples for organic acids are the mono, di and tri carboxylic acids such as acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic and sulfonic acids such as methane sulfonic acid. Salts of the carboxy terminal amino acid moiety include the non-toxic carboxylic acid salts formed with any suitable inorganic or organic bases. These salts include, for example, alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, light metals of Group IIIA including aluminium, and organic primary, secondary and tertiary amines such as trialkylamines, including triethylamine, procaine, dibenzylamine, 1-ethenamine, N,N'-dibenzylethylene-diamine, dihydroabietylamine and N-alkylpiperidine.

[0021] As used herein, the term "pharmaceutically acceptable carrier" means an inert, non toxic solid or liquid filler, diluent or encapsulating material, not reacting adversely with the active compound or with the patient. Suitable, preferably liquid carriers are well known in the art such as sterile water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and oils, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil and mineral oil.

[0022] The formulations according to the invention may be administered as unit doses containing conventional non-toxic pharmaceutically acceptable carriers, diluents, adjuvants and vehicles which are typical for parenteral administration.

[0023] The term "parenteral" includes herein subcutaneous, intravenous, intra-articular and intratracheal injection and infusion techniques. Also other administrations such as oral administration and topical application are suitable. Parenteral compositions and combinations are most preferably administered intravenously either in a bolus form or as a constant fusion according to known procedures. Tablets and capsules for oral administration contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, and wetting agents. The tablets may be coated according to methods well known in the art.

[0024] Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives like suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.

[0025] Topical applications may be in the form of aqueous or oily suspensions, solutions, emulsions, jellies or preferably emulsion ointments.

[0026] Unit doses according to the invention may contain daily required amounts of the protein according to the invention, or sub-multiples thereof to make up the desired dose. The optimum therapeutically acceptable dosage and dose rate for a given patient (mammals, including humans) depends on a variety of factors, such as the activity of the specific active material employed, the age, body weight, general health, sex, diet, time and route of administration, rate of clearance, the object of the treatment, i.e., therapy or prophylaxis and the nature of the thrombotic disease to be treated, antiplatelet or anticoagulant activity.

[0027] Therefore, in compositions and combinations useful as anticoagulants in a treated patient (in vivo) a pharmaceutical effective daily dose of the peptides of this invention is between about 0.01 and 100 mg/kg body weight, preferably between 0.1 and 10 mg/kg body weight. According to the application form one single dose may contain between 0.5 and 10 mg of the collagen inhibitor To achieve an anticoagulant effect in extracorporeal blood a pharmaceutically effective amount of the inventive peptides is between 0.2 and 150 mg/l, preferably between 1mg and 20 mg/l extracorporeal blood.

Short Description of the Figures:

[0028]

Fig.1: Protein sequence of GPVI (one-letter-code)

1a: Leader sequence

1b: Mature protein

5

Open reading frame: 339 amino acids
Asterisk: Glycosylation site
Double underline: Transmembrane domain
Underline: Sequenced peptides

10

Fig. 2: GPVI nucleotide sequence covering open reading frame of 1017 bp plus 3' and 5' regions total 1249 bp

Detailed description of the invention

15

[0029] Two sequences of 7 amino acids showing the least degeneracy in the genetic code were chosen for the synthesis of DNA primers in order to amplify part of the of GPVI cDNA by PCR. As the location of both peptides in the protein were totally unknown, for each of them, two degenerate primers, one sense and one antisense were prepared. These primers were used to amplify a human bone-marrow library. The combination of the sense 5'TYA THC CNG CNA TGA ARMG 3' primer coding for the sequence PAMKRSL with the antisense 5' TTR TAN ARN GCR AAY TGR TC 3' one corresponding to DQFALYK amplified a DNA fragment of 221 bp. In addition to the selected peptides, the amplified DNA coded for the LysC/AspN peptide DQLELVATGVFAKPSLSAQPGPAVSS, clearly linking the sequence to the cDNA for GPVI.

20

[0030] Screening 600.000 pfu from a bone marrow library with this 221 bp DNA fragment produced 4 positive pfu. Three had inserts of 1350 bp whether cut by the restriction enzymes Sal I or EcoR I and belonged to the IgG superfamily. The fourth one had an 4.6 kb insert by Sal I digestion and gave two fragments of 2300 bp and 1300 bp respectively when treated by EcoRI. Its DNA encoded the sequence for the 10 peptides derived from amino acid sequencing of GPVI but stopped short of the amino terminal. No starting methionine or leader sequence could be found but more than 2000 bp of previously sequenced non-reading frame DNA terminating in an Alu sequence were present. The 5' end RACE experiment was completed on platelet poly A RNA with primers located in a part of the GPVI sequence which had been corroborated by that of the peptides. A fragment of 348 bp including 278 bp on the sequence of the fourth clone and 70 bp new from bp 1987 corresponding to 14 amino acids including the first methionine were found before falling back on the established GPVI sequence. Thus, a cDNA containing a total of 1249 bp, a 25 bp 5' sequence upstream of the start codon, an open reading frame of 1017 bp coding for a protein, including leader sequence, with 339 amino acids, and a 3' region of 207 bp including the stop codon could be sequenced.

25

30

35

[0031] A cDNA coding for platelet GPVI was cloned and sequenced from a human bone marrow cDNA library using RACE with platelet mRNA to supply missing 5' sequence. The open reading frame of 1017 bp encodes 339 amino acids and a untranslated 3' region. Hydrophobicity analysis of the amino acid sequence revealed the presence of two putative transmembrane domains, a putative 20 amino acid signal sequence, and a 19 amino acid domain between residues 247 and 265 of the mature protein. The sequence and its amino acid translation are shown in Fig. 2 and Fig. 1. A comparison with the amino acid sequence of the most similar molecules found in a search of GenBank reveals clearly that it belongs to the immunoglobulin superfamily and the extracellular domain contains two Ig C2-domain loops formed by two disulphide bridges. It is a membrane crossing protein class one molecule with the N-terminus at the exterior and traverses the membrane once. The most closely related molecules belong to the natural killer receptor class which contains both inhibitory and activatory types. GPVI clearly belongs to the activatory subclass not only through its function but also because unlike the inhibitory class it does not contain ITIM sequences in its cytoplasmic domain. Neither does it contain any tyrosine residues which might be involved in phosphorylation. There are some threonine and serine residues in this domain but they do not match any criteria for kinase consensus sequences. Like the activatory class of NK receptors, GPVI contains an arginine residue as the third amino acid of the membrane crossing domain which is involved in the complex formation with the Fcγ subunit. The cytoplasmic domain contains 51 amino acids, showing only a minor similarity (in the region just below the membrane) to the cytoplasmic domains of other members of this family. This suggests that this domain in GPVI may associate with different types of cytoplasmic molecule than the other family members. GPVI contains only a single putative N-glycosylation site at Asn69. The domain just above the membrane after the beta sheets of the Ig domains finish, however, is rich in theonine and serine residues which could provide O-glycosylation sites such as are found in GPIbα and GPV. The main function of this O-glycosylation seems to be to present the receptor structures well-extended from the platelet surface to facilitate the interactions with their bulky ligands. Since GPVI was earlier established as a sialoglycoprotein, the difference in molecular mass between the theoretical amino acid mass (37 kDa) and the mass determined by gel electrophoresis (65 kDa reduced) must be due to this

40

45

50

55

glycosylation.

[0032] The structure of natural killer receptors of the two domain type has been established by X-ray crystallographic studies and the two Ig-domains were shown to form an acute angle with the receptor site for the peptide-carrying HLA antigens lying on the outside of the elbow. A direct comparison of the structure of the HLA peptide binding site with that of collagen immediately suggests why these receptors have a common origin because the multiple alpha-helical structures of the HLA binding site and the peptide it contains strongly resemble the triple helical structure of collagen. The natural killer receptors are postulated to work by a dimerisation mechanism with two receptors recognising two separate HLA sites on the cell which the natural killer cell is investigating. Possibly this dimerisation is part of the activation or deactivation mechanism, depending on the class of receptor. In the case of GPVI there may as well be the possibility for two GPVI molecules to associate with one Fc γ , since each monomer of the Fc γ dimer has a recognition sequence. However, the stoichiometry is not yet known, and based upon the structure of collagens, collagen-like peptides that act via GPVI and convulxin, it seems likely that the strength of the signal is related to the number of GPVI/Fc γ complexes that are clustered together. Other platelet receptors belonging to this Ig family include ICAM-2 (CD102) and PECAM (CD31).

[0033] All microorganisms, cell lines, expression systems, expression hosts, plasmids, promoters, resistance markers, replication origins, restriction sites or other fragments or parts of vectors which are mentioned in the description not directly in connection with the claimed invention are commercially or otherwise generally available. Provided that no other hints are given, they are used only as examples and are not essential with respect to the invention, and can be replaced by other suitable tools and biological materials, respectively.

[0034] The techniques which are essential according to the invention are described in detail below and above. Other techniques which are not described in detail correspond to known standard methods which are well known to a person skilled in the art, or are described more in detail in the cited references and patent applications and in the standard literature (e.g. Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor; Harlow, Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor).

EXAMPLES

[0035] Example 1: Materials-Protein A-Sepharose, peroxidase-conjugated goat antimouse and anti-rabbit antibodies, bovine serum albumin, *Crotalus durissus terrificus* venom, wheat germ agglutinin (WGA), N-hydroxysuccinimidyl chloroformate-activated cross-linked 4% beaded agarose and Triton X-114 were from Sigma Chemical Co. (St Louis, MO), Octanoyl-N-methyl-glucamide (ONMG) and nonanoyl-N-methyl-glucamide (NNMG) were from Oxyl Chemie (Bobingen, Germany).

[0036] Example 2: GPVI isolation from platelets - Membrane glycoproteins were isolated from platelets as previously described. Briefly, platelets (from 40 buffy coats) were washed and lysed in 2% Triton X-114 in the presence of protease inhibitors. The Triton X-114 and aqueous phases were separated and the detergent phase was loaded on a column of wheat-germ agglutinin coupled to Sepharose 4B. The platelet glycoproteins were eluted with 10 mM Tris HCl, pH 7.4, 30 mM NaCl, 0.2% octanoyl-N-methylglucamide (ONMG) and 2% N-acetylglucosamine. After dialysis and concentration, the solution of glycoproteins was loaded on a column of convulxin bound to N-hydroxylsuccinamidyl-p-nitrophenyl chloroformate activated cross-linked 4% beaded agarose (1 mg/ml). The column was washed with 4 volumes of 10 mM Tris HCl, pH 7.4, 30 mM NaCl, 0.2% nonanoyl-N-methylglucamide (NNMG), and then with 4 volumes of 10 mM Tris HCl, pH 7.4, 30 mM NaCl and 2% NNMG. GPVI was eluted with 0.08% SDS in 10 mM Tris/HCl, pH 7.4. The solution was concentrated and loaded on a preparative gel of 8.5 % polyacrylamide using the Model 491 Prep Cell (BioRad, CA). The preparative electrophoresis was performed under non-reduced conditions following the manufacturer instructions. GPVI eluted as a single band at 65 kDa. The fractions were pooled, concentrated on Centricon-30 (Amicon, Beverly, MA) and resuspended in 10 mM Tris/HCl, pH 7.4 and 0.1% ONMG.

[0037] Example 3: Amino acid analysis of GPVI - GPVI was digested with the endoproteinases LysC and AspN (Boehringer Mannheim, Germany). The 10 peptides generated were separated by reverse-phase HPLC and sequenced on an Applied Biosystem model 477A pulsed-liquid-phase protein sequencer with a model 120A on-line phenylthiohydantoin amino acid analyser.

[0038] Example 4: Amplification of a 221 bp fragment coding for part of GPVI from a λ gt11 cDNA library -

[0039] A sample (10^{10} pfu) (plaque forming units) from a human bone marrow library (Clonetech, Palo Alto, CA) was amplified using 2 combinations of 4 degenerate primers. The final primer concentrations were 2 μ M, the dNTP concentration was 200 μ M and 2 U/100 μ l reaction AmpliTaq Gold (Perkin Elmer, Rotkreuz, Switzerland) were used. The PCR conditions were 5 cycles at 37°C followed by 30 cycles at 44°C. The sense 19mer 5' TYATHCCNGCNATGAARMG 3' and the antisense 20mer 5' TTRTANARNGCRAAYTGRTC 3' amplified a 221 bp fragment which was subcloned in Bluescript KS⁺ (Stratagene, La Jolla, CA) and sequenced using the T7 Sequenase kit (Amersham, Switzerland).

[0040] Example 5: Screening the λ gt11 cDNA library with the 221 bp GPVI probe- The 221 bp fragment was cut from the plasmid, cleaned and labelled with α ³²P-ATP (20MBq/50 μ l, Hartmann Analytik, Braunschweig, Germany) using the High Prime Labelling kit (Boehringer Mannheim, Switzerland). The human bone marrow library was screened following

the manufacturer instructions. Positive phages were grown, their DNA isolated and subcloned in BlueScript using either EcoRI or Sal I sites and sequenced. Sequencing was performed using the ABS system of RACE- Platelet poly A RNA was prepared as previously described (Power et al., Cytokine 7, 479-482, 1995). Reverse transcription (30 μ l) was performed using 5 μ g of poly A RNA with the primer 5'TGAATGAGACGGTCAGTTCAGC 3' (20 μ M), dNTP (1mM), RNasin (40 U), 1X AMV buffer and 20 U AMV reverse transcriptase for 20 min at 45°C followed by 20 min at 52°C. The reaction mixture was treated with 2 μ l 6N NaOH at 65° C for 30 min, neutralised with 2 μ l 6N acetic acid, and concentrated in a Centricon 30 (Amicon). An anchor was ligated to the first strand DNA following the protocol of Aptes and Siebert (BioTechniques 15: 890-893, 1993). Nested PCR was performed using a primer complementary to the anchor and the primer 5' TTGTACAGAGCAAATTGGTC 3' (35 cycles, 55°C) and followed by the primer 5' GACCAGAGGCTCCGT-TCTG 3' (30 cycles at 53°C). The highest band (350 bp) was separated by agarose electrophoresis from the lower ones, subcloned into BlueScript, and sequenced.

[0041] Example 6: Preparation of anti-GPVI Fab and F(ab)₂ Polyclonal antisera against human GPVI were generated in rabbits. IgG from rabbit anti-GPVI antiserum was purified as described. Digestion of IgG with immobilized papain (Pierce) to generate Fab fragments was performed according to the standard protocol of the supplier. Fab fragments were separated from undigested IgG and Fc fragments using an immobilized Protein A (Sigma) column. The flowthrough was transferred to a dialysis tube, concentrated using solid polyethyleneglycol 20,000, thoroughly dialysed against 20 mM Hepes, 140 mM NaCl, 4 mM KCl, pH 7.4 and stored at 4°C until used. F(ab')₂ fragments were prepared by pepsin digestion of IgG, 1:50 enzyme to substrate ratio (w/w), in 0.5 M acetate buffer, pH 4.0, at 37°C for 18 hr. The pH was corrected to 7.4 with diluted NaOH and the sample was dialysed against 20 mM phosphate, pH 7.4. F(ab')₂ fragments were separated from undigested IgG and Fc fragments using Protein A chromatography. The flow-through was transferred to dialysis tube, concentrated using solid polyethyleneglycol 20 000, intensively dialysed against 20 mM Hepes, 140 mM NaCl, 4 mM KCl, pH 7.4 and stored in aliquots at -20°C. Washed platelets were lysed in Triton X-114 and phase separation was performed on the soluble material before isolating the membrane glycoproteins associated with the Triton X-114 phase by affinity chromatography on wheat germ agglutinin-Sepharose 4B as described previously. As GPVI represents a very small fraction of the platelet membrane glycoprotein pool, we used the specificity of the snake C-type lectin convulxin for isolation of this receptor. Affinity chromatography on convulxin coupled to Sepharose 4B yielded a 65 kDa protein as major product. However, uncharacterized material of both higher and lower Mr co-eluted with GPVI and could not be removed by extensive washing of the column. Preparative gel electrophoresis on 8.5 % polyacrylamide was added as a final step of purification. Fractions containing GPVI were pooled and gave a single band on reanalysis. Purified GPVI was tested for its ability to block platelet aggregation by collagen. A slight inhibitory effect was observed when aliquots of GPVI solution were added to the platelet suspension. However, by preincubating GPVI with collagen before adding the mixture to the platelet suspension, aggregation could be inhibited in a dose-dependant manner. These platelets still aggregated when fresh collagen was added. Under non-reducing conditions, the isolated protein has a Mr of 62 kDa with a shift toward a slightly higher Mr (65 kDa) under reducing conditions. As the amino terminus of GPVI was found to be blocked, the protein was digested with the enzymes LysC and LysC/AspN which produced 4 and 6 peptides, respectively, from which sequence was obtained. The peptides were separated by reverse phase HPLC on a C4 column and sequenced using the Edman method. The amino acid sequences of these peptides are underlined in the translated cDNA sequence (Fig. 1).

SEQUENCE LISTING

[0042]

<110> Merck Patent GmbH

<120> Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use

<130> GlycoproteinVI-Merck

<140>

<141>

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 1249

EP 1 177 289 B1

<212> DNA
 <213> Homo sapiens

5 <220>
 <221> CDS
 <222> (26)..(85)
 <223> Leader sequence

10 <220>
 <221> CDS
 <222> (86)..(1042)
 <223> mature GPVI protein

15 <400> 1

52	gagctcagga cagggctgag gaacc atg tct cca tcc ccg acc gcc ctc ttc	52
	Met Ser Pro Ser Pro Thr Ala Leu Phe	
	1 5	
100	20 tgt ctt ggg ctg tgt ctg ggg cgt gtg cca gcg cag agt gga ccg ctc	100
	Cys Leu Gly Leu Cys Leu Gly Arg Val Pro Ala Gln Ser Gly Pro Leu	
	10 15 20 25	
148	25 ccc aag ccc tcc ctc cag gct ctg ccc agc tcc ctg gtg ccc ctg gag	148
	Pro Lys Pro Ser Leu Gln Ala Leu Pro Ser Ser Leu Val Pro Leu Glu	
	30 35 40	
196	30 aag cca gtg acc ctc cgg tgc cag gga cct ccg ggc gtg gac ctg tac	196
	Lys Pro Val Thr Leu Arg Cys Gln Gly Pro Pro Gly Val Asp Leu Tyr	
	45 50 55	
244	35 cgc ctg gag aag ctg agt tcc agc agg tac cag gat cag gca gtc ctc	244
	Arg Leu Glu Lys Leu Ser Ser Ser Arg Tyr Gln Asp Gln Ala Val Leu	
	60 65 70	
292	40 ttc atc ccg gcc atg aag aga agt ctg gct gga cgc tac cgc tgc tcc	292
	Phe Ile Pro Ala Met Lys Arg Ser Leu Ala Gly Arg Tyr Arg Cys Ser	
	75 80 85	
340	45 tac cag aac gga agc ctc tgg tcc ctg ccc agc gac cag ctg gag ctc	340
	Tyr Gln Asn Gly Ser Leu Trp Ser Leu Pro Ser Asp Gln Leu Glu Leu	
	90 95 100 105	

EP 1 177 289 B1

gtt gcc acg gga gtt ttt gcc aaa ccc tcg ctc tca gcc cag ccc ggc 388
 Val Ala Thr Gly Val Phe Ala Lys Pro Ser Leu Ser Ala Gln Pro Gly
 110 115 120

5
 ccg gcg gtg tcg tca gga ggg gac gta acc cta cag tgt cag act cgg 436
 Pro Ala Val Ser Ser Gly Gly Asp Val Thr Leu Gln Cys Gln Thr Arg
 125 130 135

10
 tat ggc ttt gac caa ttt gct ctg tac aag gaa ggg gac cct gcg ccc 484
 Tyr Gly Phe Asp Gln Phe Ala Leu Tyr Lys Glu Gly Asp Pro Ala Pro
 140 145 150

15
 tac aag aat ccc gag aga tgg tac cgg gct agt ttc ccc atc atc acg 532
 Tyr Lys Asn Pro Glu Arg Trp Tyr Arg Ala Ser Phe Pro Ile Ile Thr
 155 160 165

20
 gtg acc gcc gcc cac agc gga acc tac cga tgc tac agc ttc tcc agc 580
 Val Thr Ala Ala His Ser Gly Thr Tyr Arg Cys Tyr Ser Phe Ser Ser
 170 175 180 185

25
 agg gac cca tac ctg tgg tcg gcc ccc agc gac ccc ctg gag ctt gtg 628
 Arg Asp Pro Tyr Leu Trp Ser Ala Pro Ser Asp Pro Leu Glu Leu Val
 190 195 200

30
 gtc aca gga acc tct gtg acc ccc agc cgg tta cca aca gaa cca cct 676
 Val Thr Gly Thr Ser Val Thr Pro Ser Arg Leu Pro Thr Glu Pro Pro
 205 210 215

35
 tcc tcg gta gca gaa ttc tca gaa gcc acc gct gaa ctg acc gtc tca 724
 Ser Ser Val Ala Glu Phe Ser Glu Ala Thr Ala Glu Leu Thr Val Ser
 220 225 230

40
 ttc aca aac aaa gtc ttc aca act gag act tct agg agt atc acc acc 772
 Phe Thr Asn Lys Val Phe Thr Thr Glu Thr Ser Arg Ser Ile Thr Thr
 235 240 245

45
 agt cca aag gag tca gac tct cca gct ggt cct gcc cgc cag tac tac 820
 Ser Pro Lys Glu Ser Asp Ser Pro Ala Gly Pro Ala Arg Gln Tyr Tyr
 250 255 260 265

50
 acc aag ggc aac ctg gtc cgg ata tgc ctc ggg gct gtg atc cta ata 868
 Thr Lys Gly Asn Leu Val Arg Ile Cys Leu Gly Ala Val Ile Leu Ile
 270 275 280

55
 atc ctg gcg ggg ttt ctg gca gag gac tgg cac agc cgg agg aag cgc 916
 Ile Leu Ala Gly Phe Leu Ala Glu Asp Trp His Ser Arg Arg Lys Arg
 285 290 295

60
 ctg cgg cac agg ggc agg gct gtg cag agg ccg ctt ccg ccc ctg ccg 964
 Leu Arg His Arg Gly Arg Ala Val Gln Arg Pro Leu Pro Pro Leu Pro
 300 305 310

65
 ccc ctc ccg cag acc cgg aaa tca cac ggg ggt cag gat gga ggc cga 1012
 Pro Leu Pro Gln Thr Arg Lys Ser His Gly Gly Gln Asp Gly Gly Arg
 315 320 325

70
 cag gat gtt cac agc cgc ggg tta tgt tca tgaccgctga accccaggca 1062
 Gln Asp Val His Ser Arg Gly Leu Cys Ser
 330 335

EP 1 177 289 B1

5 cggtcgtatc caagggaggg atcatggcat gggaggcgac tcaaagactg gcgtgtgtgg 1122
agcgtggaag caggagggca gaggctacag ctgtggaaac gaggccatgc tgcctcctcc 1182
tgggtgtcca tcagggagcc gttcggccag tgtctgtctg tctgtctgcc tctctgtctg 1242
agggcac 1249

10 <210> 2
<211> 20
<212> PRT
<213> Homo sapiens

15 <400> 2

20 Met Ser Pro Ser Pro Thr Ala Leu Phe Cys Leu Gly Leu Cys Leu Gly
1 5 10 15
Arg Val Pro Ala
20

25 <210> 3
<211> 319
<212> PRT
<213> Homo sapiens

30 <400> 3

35

40

45

50

55

EP 1 177 289 B1

Gln Ser Gly Pro Leu Pro Lys Pro Ser Leu Gln Ala Leu Pro Ser Ser
 1 5 10 15
 5 Leu Val Pro Leu Glu Lys Pro Val Thr Leu Arg Cys Gln Gly Pro Pro
 20 25 30
 Gly Val Asp Leu Tyr Arg Leu Glu Lys Leu Ser Ser Ser Arg Tyr Gln
 35 40 45
 10 Asp Gln Ala Val Leu Phe Ile Pro Ala Met Lys Arg Ser Leu Ala Gly
 50 55 60
 Arg Tyr Arg Cys Ser Tyr Gln Asn Gly Ser Leu Trp Ser Leu Pro Ser
 65 70 75 80
 15 Asp Gln Leu Glu Leu Val Ala Thr Gly Val Phe Ala Lys Pro Ser Leu
 85 90 95
 Ser Ala Gln Pro Gly Pro Ala Val Ser Ser Gly Gly Asp Val Thr Leu
 100 105 110
 Gln Cys Gln Thr Arg Tyr Gly Phe Asp Gln Phe Ala Leu Tyr Lys Glu
 115 120 125
 25 Gly Asp Pro Ala Pro Tyr Lys Asn Pro Glu Arg Trp Tyr Arg Ala Ser
 130 135 140
 Phe Pro Ile Ile Thr Val Thr Ala Ala His Ser Gly Thr Tyr Arg Cys
 145 150 155 160
 30 Tyr Ser Phe Ser Ser Arg Asp Pro Tyr Leu Trp Ser Ala Pro Ser Asp
 165 170 175

35

40

45

50

55

EP 1 177 289 B1

Pro Leu Glu Leu Val Val Thr Gly Thr Ser Val Thr Pro Ser Arg Leu
180 185 190

5 Pro Thr Glu Pro Pro Ser Ser Val Ala Glu Phe Ser Glu Ala Thr Ala
195 200 205

Glu Leu Thr Val Ser Phe Thr Asn Lys Val Phe Thr Thr Glu Thr Ser
210 215 220

10 Arg Ser Ile Thr Thr Ser Pro Lys Glu Ser Asp Ser Pro Ala Gly Pro
225 230 235 240

Ala Arg Gln Tyr Tyr Thr Lys Gly Asn Leu Val Arg Ile Cys Leu Gly
15 245 250 255

Ala Val Ile Leu Ile Ile Leu Ala Gly Phe Leu Ala Glu Asp Trp His
260 265 270

20 Ser Arg Arg Lys Arg Leu Arg His Arg Gly Arg Ala Val Gln Arg Pro
275 280 285

Leu Pro Pro Leu Pro Pro Leu Pro Gln Thr Arg Lys Ser His Gly Gly
290 295 300

25 Gln Asp Gly Gly Arg Gln Asp Val His Ser Arg Gly Leu Cys Ser
305 310 315

30 <160> 3

Claims

- 35 1. DNA coding for Glycoprotein VI.
2. DNA having the sequence of Fig. 2
3. DNA according to claims 1 or 2 coding for Glycoprotein VI comprising the amino acid sequence of Fig. 1a and 1b.
- 40 4. Recombinant human Glycoprotein VI for use as medicament comprising the amino acid sequence of Fig. 1b.
5. Pharmaceutical composition comprising the protein of claim 4 and a pharmaceutically acceptable diluent, carrier or excipient therefore, for use as a medicament.
- 45 6. Pharmaceutical composition according to claim 5 comprising additionally a pharmacologically active compound.
7. Use of recombinant GPVI for the manufacture of a medicament in the therapeutical field of thrombotic and cardiovascular diseases and disorders related to platelet-collagen interactions.
- 50 8. In vitro use of changes of binding and degree of activation of platelets by GPVI-specific snake venom proteins such as convulxin, or of changes of binding by monoclonal or polyclonal antibodies recognising the N-terminal domain of GPVI, as a marker of platelet age.
- 55 9. Use of changes according to claim 8, as a marker for diseases affecting the bone marrow or the immune system.

Patentansprüche

1. DNA, codierend für Glykoprotein VI.
- 5 2. DNA mit der Sequenz in Fig. 2.
3. DNA gemäß Anspruch 1 oder 2, codierend für Glykoprotein VI, das die Aminosäuresequenz in Fig. 1a und 1b umfaßt.
- 10 4. Rekombinantes menschliches Glykoprotein VI, umfassend die Aminosäuresequenz in Fig. 1b, zur Verwendung als Arzneimittel.
5. Pharmazeutische Zusammensetzung, umfassend das Protein nach Anspruch 4 sowie ein pharmazeutisch unbedenkliches Verdünnungs-, Träger- oder Hilfsmittel dafür, zur Verwendung als Arzneimittel.
- 15 6. Pharmazeutische Zusammensetzung gemäß Anspruch 5, zusätzlich umfassend eine pharmakologisch wirksame Verbindung.
7. Verwendung von rekombinantem GPVI zur Herstellung eines Arzneimittels auf dem Gebiet der Therapie thrombotischer und kardiovaskulärer Krankheiten und Störungen in Verbindung mit Plättchen-Kollagen-Wechselwirkungen.
- 20 8. In-vitro-Verwendung von Veränderungen bei der Bindung und dem Grad der Aktivierung von Blutplättchen durch GPVI-spezifische Schlangengiftproteine, wie etwa Convulxin, oder von Veränderungen bei der Bindung durch die N-terminale GPVI-Domäne erkennende monoklonale oder polyklonale Antikörper als Marker für das Plättchenalter.
- 25 9. Verwendung von Veränderungen gemäß Anspruch 8 als Marker für sich auf das Knochenmark oder das Immunsystem auswirkende Krankheiten.

Revendications

- 30 1. ADN codant pour la glycoprotéine VI.
2. ADN ayant la séquence de la figure 2.
- 35 3. ADN selon les revendications 1 ou 2, codant pour la glycoprotéine VI comprenant la séquence d'acides aminés des figures la et 1b.
4. Glycoprotéine VI humaine recombinante destinée à être utilisée comme médicament, comprenant la séquence d'acides aminés de la figure 1b.
- 40 5. Composition pharmaceutique comprenant la protéine selon la revendication 4 et un diluant, support ou excipient pharmaceutiquement acceptable pour celle-ci, destinée à être utilisée comme médicament.
- 45 6. Composition pharmaceutique selon la revendication 5, comprenant en outre un composé pharmacologiquement actif.
7. Utilisation d'une GPVI recombinante pour la fabrication d'un médicament s'inscrivant dans le domaine thérapeutique des maladies thrombotiques et cardiovasculaires et des troubles liés aux interactions plaquettes-collagène.
- 50 8. Utilisation in vitro de changements de la liaison et du degré d'activation des plaquettes par des protéines de venin de serpent spécifiques de la GPVI telles que la convulxine, ou de changements de la liaison par des anticorps monoclonaux ou polyclonaux reconnaissant le domaine N-terminal de la GPVI, comme marqueur de l'âge des plaquettes.
- 55 9. Utilisation de changements selon la revendication 8, comme marqueur de maladies affectant la moelle osseuse ou le système immunitaire.

Figure 2:

GAGCTCAGGA CAGGGCTGAG GAACCATGTC TCCATCCCCG ACCGCCCTCT (50)
 TCTGTCTTGG GCTGTGTCTG GGGGCTGTGC CAGCGCAGAG TGGACCGCTC (100)
 CCCAAGCCCT CCCTCCAGGC TCTGCCAGC TCCCTGGTGC CCCTGGAGAA
 GCCAGTGACC CTCCGGTGCC AGGGACCTCC GGGCGTGGAC CTGTACCGCC (200)
 TGGAGAAGCT GAGTTCCAGC AGGTACCAGG ATCAGGCAGT CCTCTTCATC
 CCGGCCATGA AGAGAAGTCT GGCTGGACGC TACCGCTGCT CCTACCAGAA (300)
 CGGAAGCCTC TGGTCCCTGC CCAGCGACCA GCTGGAGCTC GTTGCCACGG
 GAGTTTTTGC CAAACCCTCG CTCTCAGCCC AGCCCGGCCG GGCGGTGTCTG (400)
 TCAGGAGGGG ACGTAACCCT ACAGTGTGAG ACTCGGTATG GCTTTGACCA
 ATTTGCTCTG TACAAGGAAG GGGACCCTGC GCCCTACAAG AATCCCGAGA (500)
 GATGGTACCG GGCTAGTTTC CCCATCATCA CGGTGACCGC CGCCCACAGC
 GGAACCTACC GATGCTACAG CTTCTCCAGC AGGGACCCAT ACCTGTGGTC (600)
 GGCCCCCAGC GACCCCTGG AGCTTGTGGT CACAGGAACC TCTGTGACCC
 CCAGCCGGTT ACCAACAGAA CCACCTTCCT CGGTAGCAGA ATTCTCAGAA (700)
 GCCACCGCTG AACTGACCGT CTCATTCACA AACAAAGTCT TCACAACCTGA
 GACTTCTAGG AGTATCACCA CCAGTCCAAA GGAGTCAGAC TCTCCAGCTG (800)
 GTCCTGCCCCG CCAGTACTAC ACCAAGGGCA ACCTGGTCCG GATATGCCTC
 GGGGCTGTGA TCCTAATAAT CCTGGCGGGG TTTCTGGCAG AGGACTGGCA (900)
 CAGCCGGAGG AAGCGCCTGC GGCACAGGGG CAGGGCTGTG CAGAGGCCGC
 TTCCGCCCTT GCCGCCCTC CCGCAGACC GGAAATCACA CGGGGGTCAG (1000)
 GATGGAGGCC GACAGGATGT TCACAGCCGC GGGTTATGTT CATGACCGCT
 GAACCCAGG CACGGTCGTA TCCAAGGGAG GGATCATGGC ATGGGAGGCG (1100)
 ACTCAAAGAC TGGCGTGTGT GGAGCGTGGA AGCAGGAGGG CAGAGGCTAC
 AGCTGTGGAA ACGAGGCCAT GCTGCCTCCT CCTGGTGTTT CATCAGGGAG (1200)
 CCGTTCGGCC AGTGTCTGTC TGTCTGTCTG CCTCTCTGTC TGAGGGCAC (1249)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **GIBBINS JONATHAN M et al.** *FEBS LETTERS*, 1997, vol. 413 (2), 255-259 [0005]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, 1989 [0034]
- **HARLOW ; LANE.** *Antibodies: A Laboratory Manual*. Cold Spring Harbor, 1988 [0034]
- *Power*, 1995, vol. 7, 479-482 [0040]
- *BioTechniques*, 1993, vol. 15, 890-893 [0040]

专利名称(译)	重组血小板胶原受体糖蛋白vi及其药物用途		
公开(公告)号	EP1177289B1	公开(公告)日	2008-04-23
申请号	EP2000927035	申请日	2000-04-25
申请(专利权)人(译)	MERCK PATENT GMBH		
当前申请(专利权)人(译)	SANOFI-AVENTIS DEUTSCHLAND GMBH		
[标]发明人	CLEMETSON KENNETH J		
发明人	CLEMETSON, KENNETH, J.		
IPC分类号	C12N15/12 C07K14/705 A61K38/17 G01N33/68 G01N33/50 A61K38/00 A61P7/02 A61P9/10 C07K14/755 C12N15/09 G01N15/00 G01N33/15 G01N33/53 G01N33/86		
CPC分类号	A61K38/00 A61P7/02 A61P9/08 A61P9/10 C07K14/70503 C07K14/755 C07K16/2803 C07K2317/54 C07K2317/55 G01N33/86 G01N2015/0084 G01N2333/4728 G01N2333/78 G01N2500/02 G01N2800/222 C07K14/745 C07K16/28 C07K2317/20 C07K2317/76		
优先权	1999109094 1999-05-07 EP		
其他公开文献	EP1177289A1		
外部链接	Espacenet		

摘要(译)

本发明涉及糖蛋白VI (GPVI)，其分离，纯化和重组生产方法。特别地，本发明涉及GPVI，优选重组GPVI在治疗与血液凝固障碍如血栓形成和心血管疾病直接或间接相关的病症和病理事件中的用途。细胞外重组蛋白也可用于建立筛选试验，以找到膜结合GPVI的潜在抑制剂，以分别抑制血小板和血小板与胶原的结合。 GPIV的变化可用于监测血小板年龄和血栓和心血管疾病的暴露。

```

gagctcagga caggctgag gaacc atg tct cca tcc ccg acc gcc ctc ttc 52
Met Ser Pro Ser Pro Thr Ala Leu Phe
1 5
tgt ctt ggg ctg tgt ctg ggg cgt gtg cca gcg cag agt gga ccg ctc 100
Cys Leu Gly Leu Cys Leu Gly Arg Val Pro Ala Gln Ser Gly Pro Leu
10 15 20 25
ccc aag ccc tcc ctg cag gct ctg ccc agc tcc ctg gtg ccc ctg gag 148
Pro Lys Pro Ser Leu Gln Ala Leu Pro Ser Ser Leu Val Pro Leu Glu
30 35 40
aag cca gtg acc ctg cgg tgc cag gga cct ccg gcc gtg gac ctg tac 196
Lys Pro Val Thr Leu Arg Cys Gln Gly Pro Pro Gly Val Asp Leu Tyr
45 50 55
cgc ctg gag aag ctg agt tcc agc agg tac cag gat cag gca gtc ctc 244
Arg Leu Glu Lys Leu Ser Ser Ser Arg Tyr Gln Asp Gln Ala Val Leu
60 65 70
ttc atc ccg gcc atg aag aga agt ctg gct gga cgc tac cgc tgc tcc 292
Phe Ile Pro Ala Met Lys Arg Ser Leu Ala Gly Arg Tyr Arg Cys Ser
75 80 85
tac cag aac gga agc ctg tgg tcc ctg ccc agc gac cag ctg gag ctc 340
Tyr Gln Asn Gly Ser Leu Trp Ser Leu Pro Ser Asp Gln Leu Glu Leu
90 95 100 105

```